Early Rheumatoid Arthritis Clinical Trial
Official title:
Effect of Early Intensive Treatment in Chinese Patients With Recent-onset Rheumatoid Arthritis
NCT number | NCT01762176 |
Other study ID # | ERA-MRI-2012 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | October 2012 |
Est. completion date | July 2018 |
Verified date | September 2023 |
Source | Chinese University of Hong Kong |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To compare the effectiveness of two treatment strategies in early rheumatoid arthritis (ERA), namely the delayed usual care and early intensive care, in Hong Kong. - The delayed usual care reflects the usual treatment practice in Hong Kong - The early intensive care includes tight monitoring and immediate adjustment of therapy
Status | Completed |
Enrollment | 163 |
Est. completion date | July 2018 |
Est. primary completion date | July 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: For usual care group: - patients with at least 1 tender and swollen joint - duration of symptoms less than 2 years - no previous use of DMARDs For intensive care group: - patients with at least 1 tender and swollen joint - duration of symptoms less than 2 years - no previous use of DMARDs - patients who fulfill the 2010 ACR/EULAR classification criteria for RA Exclusion Criteria: - patients with renal impairment (on dialysis or estimated Glomerular Filtration Rate (eGFR) <30 mL/min/1.73m^2) |
Country | Name | City | State |
---|---|---|---|
China | Prince of Wales Hospital | Hong Kong |
Lead Sponsor | Collaborator |
---|---|
Chinese University of Hong Kong |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The proportion of patients who achieve clinical remission | The clinical remission is defined using the latest ACR/EULAR remission criteria (Boolean criteria) | 12 months | |
Secondary | Change in various patient-reported outcomes | The various patient-reported outcomes include employment status, Working Ability Index (WAI), disability index of Health Assessment Questionnaire (HAQ), Functional Assessment of Chronic Illness Therapy (FACIT), Hospital Anxiety and Depression Scale (HADS) and Health-related quality of life (HRQoL) generic measures | 12 months | |
Secondary | Gains in utility | The Utility score is calculated by EQ-5D self-report questionnaire, which provides a single index value for health status that can be used in the clinical and economic appraisal. Value set derived from a Chinese cohort in Beijing is used, since no value set for Hong Kong Chinese population is available. | 12 months | |
Secondary | Radiographic progression | Radiographic progression expressed using the van der Hejide modification of the Sharp scored | 12 months | |
Secondary | ACR 20, 50, 70 responses | The ACR 20, 50, 70 responses are defined as at least 20%, 50%, 70% improvement in joint swelling and joint tenderness counts, and at least three of five other variables (i.e. erythrocyte sedimentation rate, HAQ score, pain score, and physicians' and patients' global assessments) | 12 months | |
Secondary | MRI outcome | MRI image set is evaluated and scored separately for the presence or absence of MRI erosion, synovitis, and bone marrow oedema. Bone erosions and bone marrow oedema are evaluated separately in each wrist bone, whereas synovitis is evaluated in the three regions of the wrist joint: the radioulnar area, the radiocarpal area, and the intercarpal-carpometacarpal area. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01768923 -
Early RA Vascular Randomised Controlled Study
|
N/A | |
Completed |
NCT01185301 -
Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)
|
Phase 3 | |
Recruiting |
NCT03755258 -
Trial of Ginsenoside Compound K (GCK) Tablet in Patients With Rheumatoid Arthritis
|
Phase 1 | |
Recruiting |
NCT03389711 -
INCMNSZ - Rheumatoid Arthritis Cohort
|
||
Completed |
NCT00195663 -
Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT04752748 -
Power Doppler in Hand Joints of Early RA Patients
|